Is Pegasys approved for hepatitis B?
Yes, Pegasys (peginterferon alfa-2a) is FDA-approved for chronic hepatitis B in adults and children aged 3 and older. It treats both HBeAg-positive and HBeAg-negative forms, aiming to achieve viral suppression and seroconversion.[1][2]
How does Pegasys work for hep B?
Pegasys, a pegylated interferon, boosts the immune response against the hepatitis B virus (HBV). Given as weekly subcutaneous injections for 48 weeks, it reduces HBV DNA levels and normalizes liver enzymes in about 30-40% of patients, though response rates vary by genotype and patient factors.[1][3]
Pegasys vs. other hep B treatments
Pegasys differs from nucleoside/nucleotide analogs like entecavir or tenofovir, which suppress the virus long-term but rarely cure it. Interferons like Pegasys offer a finite treatment course with potential for HBsAg loss (functional cure) in 3-10% of cases, but they have more side effects. Guidelines often prefer oral antivirals first-line due to better tolerability.[2][4]
Common side effects and patient concerns
Patients report flu-like symptoms, fatigue, depression, and blood count drops. Monitoring for thyroid issues and retinopathy is required. It's less used today due to these tolerability issues compared to oral options.[1][3]
Availability, patents, and generics
Pegasys, made by Genentech (Roche), launched in 2002. Key U.S. patents expired around 2019-2022, allowing generics or biosimilars in some markets, though no FDA-approved biosimilar exists yet in the U.S. Check DrugPatentWatch.com for exact expiry dates and litigation.[5]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103964s5253lbl.pdf
[2] AASLD Guidelines: https://www.aasld.org/practice-guidelines/chronic-hepatitis-b
[3] EASL Guidelines: https://easl.eu/publication/hepatitis-b-guidelines/
[4] NIH Hep B Info: https://www.niddk.nih.gov/health-information/liver-disease/viral-hepatitis/hepatitis-b
[5] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/PEGASYS